288 related articles for article (PubMed ID: 32447327)
1. Medical treatment in thyroid eye disease in 2020.
Khong JJ; McNab A
Br J Ophthalmol; 2021 Mar; 105(3):299-305. PubMed ID: 32447327
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease.
Strianese D
Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S56-S59. PubMed ID: 29923966
[TBL] [Abstract][Full Text] [Related]
3. Advances in the management of thyroid eye diseases: An overview.
Kumari R; Chandra Saha B
Int Ophthalmol; 2018 Oct; 38(5):2247-2255. PubMed ID: 28822031
[TBL] [Abstract][Full Text] [Related]
4. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
5. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
Smith TJ
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
[TBL] [Abstract][Full Text] [Related]
6. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
7. The Role of Biological Agents and Immunomodulators in Treatment Strategies for Thyroid Eye Disease: An Evidence-based Review.
Ginter A; Migliori ME
R I Med J (2013); 2016 Jun; 99(6):26-9. PubMed ID: 27247969
[TBL] [Abstract][Full Text] [Related]
8. Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
Bello OM; Druce M; Ansari E
BMJ Open Ophthalmol; 2024 Jun; 9(1):. PubMed ID: 38886120
[TBL] [Abstract][Full Text] [Related]
9. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL; Douglas R; Dosiou C
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
12. The pathophysiology of thyroid eye disease: implications for immunotherapy.
Douglas RS; Gupta S
Curr Opin Ophthalmol; 2011 Sep; 22(5):385-90. PubMed ID: 21730841
[TBL] [Abstract][Full Text] [Related]
13. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
[TBL] [Abstract][Full Text] [Related]
14. Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy.
Kotwal A; Stan M
Horm Metab Res; 2018 Dec; 50(12):871-886. PubMed ID: 30286486
[TBL] [Abstract][Full Text] [Related]
15. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease.
Strianese D
Curr Opin Ophthalmol; 2017 Sep; 28(5):505-513. PubMed ID: 28700384
[TBL] [Abstract][Full Text] [Related]
16. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic.
Shen S; Chan A; Sfikakis PP; Hsiu Ling AL; Detorakis ET; Boboridis KG; Mavrikakis I
Surv Ophthalmol; 2013; 58(3):252-65. PubMed ID: 23253433
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
18. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
20. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
Edmunds MR; Boelaert K
Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
